Biofrontera Inc.

Good morning, and welcome to the BioFrontera, Inc. First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Tirth Patel with LHA Investor Relations. Please go ahead, sir.

Good morning, and welcome to Biofrontera Inc.' 's first quarter 2022 financial results conference call. Please note that certain information discussed during today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied in by these forward-looking statements due to risks and uncertainty associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontera's press releases and SEC filings. Also, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, May 13, 2022. BioFrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Our friend Tara believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. More specifically, Management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net income or loss excluding interest, income, and expense, income taxes, depreciation, and amortization, legal settlement expense, and certain other non-recurring or non-cash items. With that, I would like to turn the call over to Herman Loubert, Executive Chairman of BioFrontera, Inc.

Thank you, Tov. and welcome everyone to BioFrontera Inc's first quarter 2022 financial results conference call. Joining me today is Erika Monaco, our Chief Executive Officer. In a moment, Erika will review the business, our strategy, and our recent financial results. But first, I would like to say a few words. I'm very proud of the hard work by the entire BioFrontera team to generate such strong first quarter financial results following a foundational year that included our successful IPO. I interpret these results as confirmation of the data-driven approach to providing guidance and direction to our sales force we have initiated about one year ago. It's clear that BioFrontera has significant market opportunity ahead of us, and I'm confident in this team's ability to capture it. We are focused, we are thoughtful, and we are driven. Adoption of photodynamic therapy is growing, as are the clinical successes among BioFrontera-sponsored and investigator-initiated studies with our products. Establishing our position as the leader in PDT and expanding the Amalus label to deliver innovative solutions for patients are the key mechanisms to unlock the drug's potential. We look forward to providing clinical updates on the three ongoing trials by our licensed partner as they become available. With that, I'll turn the call over to Erica.